The issue with mass-marketed compounded drugs like Wegovy extends beyond IP infringement. It attacks the fundamental "social contract" of biopharma: companies invest billions in R&D for a period of market exclusivity. Allowing compounded copies to bypass this system erodes the incentive for all future drug development.

The weight-loss drug market is a duopoly, not a monopoly, because companies cannot patent the underlying biological mechanism (mimicking GLP-1). Instead, Novo Nordisk and Eli Lilly patented distinct molecules that achieve a similar outcome, allowing both to compete directly.

After a successful trial showed GIK could halve cardiac arrest and mortality, researchers were surprised it wasn't adopted. Pharmaceutical companies refused to manufacture the simple glucose, insulin, and potassium mixture because it didn't fit their business model of patenting a new drug and marketing it heavily. This forced the researchers to form their own company.

Many peptides are unlikely to ever receive FDA approval because their simple, easily replicated structures make them commodities. Pharma companies won't fund billion-dollar trials for drugs they can't patent, leaving them in a permanent gray market.

Biotech companies are incentivized to own the entire intellectual property for a drug, from delivery to molecule. This leads to endless litigation and siloed innovation, preventing the combination of "best-in-class" components from different companies and ultimately slowing progress for patients.

Andrew Huberman suggests that an impending crackdown on gray market peptides is motivated by pharmaceutical giant Eli Lilly's desire to protect its patent on Retatrutide, a potential trillion-dollar weight-loss drug. The push for regulation may be less about public safety and more about eliminating low-cost, gray-market alternatives to a blockbuster product.

The fastest, cheapest path to drug approval involves showing a small survival benefit in terminally ill patients. This economic reality disincentivizes the longer, more complex trials required for early-stage treatments that could offer a cure.

Developing an antibiotic is costly, but its use is short-term and new drugs are held in reserve, making them unprofitable. This market failure, not a lack of scientific capability, has caused pharmaceutical companies to exit the space, creating a worsening global health crisis.

R&D departments in large pharmaceutical companies often resist repurposing projects. Their leaders are rewarded for discovering new chemical entities, not for finding new applications for existing drugs, creating an internal funding barrier that business units must overcome.